| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | Axitinib | FIMM | pan-cancer | AAC | 0.12 | 0.5 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | -0.22 | 0.5 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | -0.026 | 0.5 |